Pipazethate is a synthetic, non-selective dopamine receptor antagonist. It is a relatively potent antagonist at D1, D2, D3, and D4 receptors, with an affinity for D2 receptors being slightly greater than that for D1 receptors. The drug is of interest due to its ability to improve cognitive function in patients with Alzheimer's disease and other cognitive disorders. It is also being investigated for its potential to treat addiction, Parkinson's disease, and Huntington's disease. Pipazethate has been shown to improve memory and attention in animal models of Alzheimer's disease. However, there is no current clinical evidence to support the use of pipazethate for the treatment of Alzheimer's disease or other cognitive disorders. It is important to note that pipazethate has not been approved for use in the United States and is currently only available for research purposes.'
pipazethate: RN given refers to parent cpd; structure
ID Source | ID |
---|---|
PubMed CID | 22425 |
CHEMBL ID | 2104900 |
CHEBI ID | 135635 |
SCHEMBL ID | 149990 |
MeSH ID | M0065813 |
Synonym |
---|
theratuss |
d 254 |
10h-pyrido(3,2-b)(1,4)benzothiazine-10-carboxylic acid, 2-(2-piperidinoethoxy)ethyl ester |
einecs 218-508-8 |
pipazethate |
2-(2-piperidinoethoxy)ethyl 10h-pyrido(3,2-b)(1,4)benzothiazine-10-carboxylate |
pipazetatum [inn-latin] |
pipazetato [inn-spanish] |
lenopect |
brn 1091957 |
skf 70230 a |
sq 15874 |
pipazetate |
10h-pyrido(3,2-b)(1,4)benzothiazine-10-carboxylic acid, 2-(2-(1-piperidinyl)ethoxy)ethyl ester |
pipazetate (inn) |
pipazethate (usan) |
2167-85-3 |
D05484 |
CHEBI:135635 |
DB08796 |
2-(2-piperidin-1-ylethoxy)ethyl pyrido[3,2-b][1,4]benzothiazine-10-carboxylate |
pipazethate [usan] |
m5ek1t5v2l , |
d-254 |
sk&f 70230-a |
pipazetate [inn] |
sq 15,874 |
pipazetatum |
pipazetato |
unii-m5ek1t5v2l |
sq-15874 |
so 15,874 |
CHEMBL2104900 |
SCHEMBL149990 |
pipazetate [who-dd] |
2-(2-piperidinoethoxy)ethyl 10h-pyrido[3,2-b][1,4]benzothiazine-10-carboxylate |
pipazethate [mi] |
sk&f-70230-a |
pipazetate [mart.] |
2-(2-piperidinoethoxy)ethyl 10h-pyrido[3,2-b][1,4]benzothiadiazine-10-carboxylate |
10h-pyrido[3,2-b][1,4]benzothiazine-10-carboxylic acid, 2-(2-piperidinoethoxy)ethyl ester |
skf 70230-a |
DTVJXCOMJLLMAK-UHFFFAOYSA-N |
10h-pyrido[3,2-b][1,4]benzothiazine-10-carboxylic acid, 2-[2-(1-piperidinyl)ethoxy]ethyl ester |
2-[2-(1-piperidinyl)ethoxy]ethyl 10h-pyrido[3,2-b][1,4]benzothiazine-10-carboxylate # |
DTXSID40176056 |
2-[2-(piperidin-1-yl)ethoxy]ethyl 9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(10),3,5,7,11,13-hexaene-2-carboxylate |
pipazetat |
Q7197205 |
skf 70230a; sq 15874;d 254;pipazetate |
CS-0017506 |
HY-B2090 |
AKOS040753563 |
The developed methods were validated in accordance with ICH guidelines. They successfully applied to the analysis of pipazethate HCl in dosage forms with good accuracy and precision.
Excerpt | Relevance | Reference |
---|---|---|
"Three simple, sensitive, precise, reproducible and validated spectrophotometric methods have been developed for the quantification of pipazethate HCl as antitussive drug in pure and dosage forms." | ( Utilization of N-bromosuccinimide for the sensitive spectrophotometric determination of pipazethate HCl as antitussive drug in pure and dosage forms. Abourehab, MAS; Ellateif, A; Fawzi, SM; Gouda, AA; Shahin, MHK; Sheikh, RE, 2021) | 1.05 |
"The developed methods were validated in accordance with ICH guidelines and successfully applied to the analysis of pipazethate HCl in dosage forms with good accuracy and precision." | ( Utilization of N-bromosuccinimide for the sensitive spectrophotometric determination of pipazethate HCl as antitussive drug in pure and dosage forms. Abourehab, MAS; Ellateif, A; Fawzi, SM; Gouda, AA; Shahin, MHK; Sheikh, RE, 2021) | 1.05 |
Class | Description |
---|---|
aryl sulfide | Any organic sulfide in which the sulfur is attached to at least one aromatic group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (60.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 4 (26.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (6.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.06) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 3 (17.65%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (82.35%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |